Anti-HBV Drugs: Progress, Unmet Needs, and New Hope
Open Access
- 15 September 2015
- Vol. 7 (9) , 4960-4977
Abstract
Approximately 240 million people worldwide are chronically infected with hepatitis B virus (HBV), which represents a significant challenge to public health. The current goal in treating chronic HBV infection is to block progression of HBV-related liver injury and inflammation to end-stage liver diseases, including cirrhosis and hepatocellular carcinoma, because we are unable to eliminate chronic HBV infection. Available therapies for chronic HBV infection mainly include nucleos/tide analogues (NAs), non-NAs, and immunomodulatory agents. However, none of them is able to clear chronic HBV infection. Thus, a new generation of anti-HBV drugs is urgently needed. Progress has been made in the development and testing of new therapeutics against chronic HBV infection. This review aims to summarize the state of the art in new HBV drug research and development and to forecast research and development trends and directions in the near future.Keywords
This publication has 88 references indexed in Scilit:
- Virtual Screening and Biological Evaluation of Inhibitors Targeting the XPA-ERCC1 InteractionPLOS ONE, 2012
- A Novel Inhibitor of Human La Protein with Anti-HBV Activity Discovered by Structure-Based Virtual Screening and In Vitro EvaluationPLOS ONE, 2012
- TIM-3 Expression Characterizes Regulatory T Cells in Tumor Tissues and Is Associated with Lung Cancer ProgressionPLOS ONE, 2012
- HBV life cycle and novel drug targetsHepatology International, 2011
- Ethanol Extract from Ampelopsis sinica Root Exerts Anti‐Hepatitis B Virus Activity via Inhibition of p53 Pathway In VitroEvidence-Based Complementary and Alternative Medicine, 2011
- Review of Hepatitis B TherapeuticsClinical Infectious Diseases, 2010
- Heat Stress Cognate 70 Host Protein as a Potential Drug Target against Drug Resistance in Hepatitis B VirusAntimicrobial Agents and Chemotherapy, 2010
- APOBEC3 proteins mediate the clearance of foreign DNA from human cellsNature Structural & Molecular Biology, 2010
- Infectivity Determinants of the Hepatitis B Virus Pre-S Domain Are Confined to the N-Terminal 75 Amino Acid ResiduesJournal of Virology, 2007
- Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogueProceedings of the National Academy of Sciences, 2007